Cerebrovascular and Brain Abnormalities In Autosomal-Dominant Polycystic Kidney Disease: Role Of 3d Time-of-Flight Magnetic Resonance Angiography by Russo Carmela et al.
a  S c i T e c h n o l  j o u r n a lResearch Article
Russo et al., J Genet Disor Genet Rep 2016, 5:3
http://dx.doi.org/10.4172/2327-5790.1000140 Journal of Genetic 
Disorders & Genetic 
Reports
All articles published in Journal of Genetic Disorders & Genetic Reports are the property of SciTechnol, and is protected by 
copyright laws. Copyright © 2016, SciTechnol, All Rights Reserved.International Publisher of Science, 
Technology and Medicine
Cerebrovascular and Brain 
Abnormalities in Autosomal-
Dominant Polycystic Kidney 
Disease: Role of 3d Time-of-
Flight Magnetic Resonance 
Angiography
Carmela Russo1, Ferdinando Caranci1, Massimo Imbriaco1, 
Manuela Napoli1, Antonio Pisani2*, Eleonora Riccio2, Michele 
Santangelo1, Sirio Cocozza1, Enrico Tedeschi1, Francesco 
Briganti3 and Arturo Brunetti1
*Corresponding author: Antonio Pisani, Department of Public Health, Section 
of Nephrology, Federico II University, via Sergio Pansini, 5, Naples, Italy, Tel: +39 
081/7464521; Fax: +39 081/7464521; E-mail: Antonio.pisani13@gmail.com 
Received: June 22, 2016 Accepted: July 11, 2016 Published: July 15, 2016
Introduction
Autosomal-dominant polycystic kidney disease (ADPKD) is the 
most frequent renal hereditary disorder. Although kidney involvement 
with progression to end stage renal disease is the most common clinical 
feature, ADPKD is a systemic disorder associated with various extra renal 
manifestations such hepatic and pancreatic cysts and cerebrovascular and 
brain abnormalities [1], that contribute to the associated morbidity and 
mortality [2]. Despite the recent basic and clinical researches ADPKD 
remains a therapeutic challenge [3-6].
Cerebrovascular complication with rupture of intracranial 
aneurysm (IAs) is the most devastating of the extra renal 
manifestations that accounts for 4% to 7% of deaths in patients with 
ADPKD and for severe neurological deficit or disability in survivals. 
Compared with the general population, patients with ADPKD have 
an increased frequency of IAs with estimates of prevalence ranging 
from 4% to 41% [7]. The subarachnoid hemorrhage (SAH) due to the 
rupture of ICANs in ADPKD occurs more often and at younger age 
compared to the general population [8]. 
In clinical practice, the indications for screening of IAs in ADPKD 
are limited to subgroups of patients with either a family history of 
IA or previous aneurysm rupture, those undergoing major elective 
surgery, or those in a high-risk occupation [8]. Unfortunately, except 
for a positive family history of SAH, no risk factors for IAs in patients 
with ADPKD have been defined [9], which means that we are not able 
to identify all patients with a risk for SAH from IA rupture. However, 
as some authors support systematic screening for IAs in patients with 
ADPKD [10], our study was designed to determine the prevalence of 
IAs or other possible vascular and cerebral abnormalities by Magnetic 
Resonance Angiography (MRA), in order to evaluate the role of MRA 
screening in these patients.
Material and Methods
All patients with a new diagnosis of ADPKD attending the 
Department of Nephrology of the Federico II University of Naples 
between January 2009 and September 2013 were considered for 
recruitment. The diagnosis of ADPKD was performed according 
to the unified ultrasonographic criteria [11] in addition to a family 
history of polycystic kidney disease. We excluded all patients with 
signs or symptoms of neurological disorders. The study was conducted 
in accordance with the Declaration of Helsinki and was approved 
by the institutional ethics committee. All patients provided written 
informed consent. Enrolled patients underwent to brain magnetic 
resonance imaging (MRI) evaluation at the Department of Diagnostic 
Imaging of Federico II University of Naples. These evaluations were 
performed per center practice with a 1.5 T MRI system (Gyroscan 
Intera, Philips Medical System, Best, The Netherlands). MRI was 
performed by using a 3-dimensional time-of-flight sequence (3D 
TOF, TE 65 ms; TR 6.9 ms; flip angle 20°; slice thickness 1.40 mm; 
FOV 175×200 mm) without contrast medium injection; maximum 
intensity projection (MIP) and multi-planar reformation (MPR) 
reconstructions were used for subsequent MRI analysis. Additionally, 
a standard Turbo-Spin-Echo (TSE) T2-weighted (w) axial sequence 
was acquired for the study of the brain (TE 100 ms; TR 4451.4 ms; slice 
thickness/gap 5.00/1.00 mm; FOV 230×184 mm). Two experienced 
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neuroradiologists examined the images in order to detect the eventual 
presence of IAs, vascular abnormalities or anatomical variants. 
Morphologic characteristics of the aneurysms and parent arteries, 
such as diameter, course and volume, were measured. Patients with 
ICANs found at MRI and normal to mild renal function (glomerular 
filtration rate, GFR>60 ml/min/1.73 m2) were subsequently 
recommended for Computed Tomography Angiography (CTA) and 
digital subtraction angiography (DSA), as a reference standard for 
comparison. Further actions were discussed with the interventional 
neuroradiologist. 
The primary analysis of this study is the estimation of the 
frequency of IAs detected in patients with ADPKD. The frequency 
was estimated and a 95% CI constructed for the estimate. Other 
data were expressed as mean ± SD and processed with the statistical 
software SPSS 15.0 (SPSS Inc). Quantitative and qualitative data were 
analyzed with variance analysis and the χ2 test, respectively. Logistic 
regression was used to analyze the factors. P<0.05 was considered 
statistically significant.
Results
We studied 31 females (F) and 25 males (M) with a mean age of 
40 years (range 24-63 years); 14 patients had a first-degree familial 
relationship, including 2 siblings. 23 patients had a positive family 
history, defined as first or second degree relatives with IAs or SAH.
The prevalence of IAs in 56 patients was 16.1%. MRI screening 
detected 9 unruptured IAs in 8 patients (4M, 4F), as 1 female patient 
showed two aneurysms. 4 patients had a positive family history of 
IAs or SAH; one of them had experienced aortic dissection (type A) 9 
months before performing MRI. All ICANs were saccular, small-size 
aneurysms, with a mean diameter of 5 mm (range 3 mm to 8 mm), and 
4 of them demonstrated wide neck. All IAs were found in the anterior 
circulation: 5 along the internal carotid artery (ICA), 1 at the anterior 
communicating artery (AcA) and 3 at the middle cerebral artery 
(MCA). Patients with IAs detected by MRI subsequently underwent 
CTA and DSA, which confirmed all 9 aneurysms. No additional 
aneurysms were found by DSA. These patients were referred to our 
center for treatment. 3 of them were lost during the follow-up. The 
female patient with two IAs had a 6 mm aneurysm at the bifurcation 
of right MCA, which was treated with microsurgical clipping. The 
patient with a 5 mm AcA IA refused both surgical and endovascular 
treatment, choosing a conservative strategy. She unfortunately 
suffered SAH 25 months after MRI and underwent clipping at 
another institution. The other ones (2F, 2M), including the patient 
with 2 IAs, underwent endovascular treatment by flow-diverter 
devices (FDD) (PIPELINE ev3 Chestnut Medical Inc.). They were 4 
small IAs: 2 of the ICA (mean diameter 3.33 mm, range 3-4 mm; neck 
mean diameter 2.5 mm, range 2.5-3 mm) (Figure 1), and 1 of the M1 
segment of the MCA (diameter 8 mm; neck 5 mm). After treatment, 
these patients were monitored for clinical evolution, patency of the 
covered vessel and aneurysmal occlusion: at 1 week by neurological 
exam, 1 month by CTA, 3 months by DSA, and 6 months by CTA 
in 1 case and by MRI in 2 cases. The follow-up images demonstrated 
total IA occlusion in all four patients: the occlusion period was 3 
months (Figures 1 and 2). Other vascular abnormalities or variants 
detected in our 56 patients included 2 cases of ICA hypoplasia, 1 
ICA dolichoectasia, 1 basilar artery (BA) dolichoectasia, 3 cases of 
ICA kinking (extra cranial segment), 1 BA hypoplasia, 14 vertebral 
artery (VA) asymmetries (two for unilateral hypoplasia), 4 anterior 
cerebral arteries (ACA) asymmetries (unilateral hypoplasia of A1 
horizontal segment), 1 ACA trifurcation, 2 posterior cerebral artery 
(PCA) “fetal” origin, 1 venous drainage anomaly. Additional findings 
included arachnoid cysts in 4 patients, large bilateral choroid plexus 
cysts in 1 patient and a mega cisterna magna in 2 patients.
Discussion
The well-known association between ADPKD, IAs and other 
intracranial vascular abnormalities has been attributed both to the 
contributory role of acquired factors as cigarette smoking and arterial 
hypertension as in the general population, both to PKD1 and PKD2 
mutations which play a role in the structural integrity of blood vessels 
[12].
Polycystins could be instrumental in the functional interaction 
between arterial smooth muscle cells and adjacent elastic tissue 
or endothelial cells, so a mutation in their genes could disrupt this 
interaction and weakens the vessel wall [13].
ADPKD individuals have a higher prevalence of IAs than the 
general population. Three large studies have found a prevalence range 
of IAs of 4% to 11.7%, in contrast to the 1% prevalence in the general 
population [14-17].
In our series, we found a prevalence of 16.1% for IAs in patients 
with ADPKD, which is higher than the above mentioned reports, 
but it is similar to the prevalence of asymptomatic IAs in patients 
with ADPKD and a familial history of IA or SAH found in a study 
by Pirson et al. [8], and to the prevalence found by Niemczyk et al 
in a sample of Polish patients [18]. Moreover, the distribution of IAs 
between female and male patients was equal in our series, according 
to previous reports [2,9]. The characteristics of IAs differ between our 
series and some of the previous reports. MCA is the most frequent 
site of IAs in ADPKD patients and almost 5% to 10% IAs are located 
in the posterior circulation, whereas ICA is the most frequent site of 
IAs in the general population. In our study, IAs were most frequently 
located in the ICA (5/9), accounting for more than half of the detected 
IAs; no IA was detected in the posterior circulation. To our knowledge 
this is the first Italian MRA screening study on ADPKD population 
reported in literature in the last 20 years. We studied 56 patients 
coming from Southern Italy and we could attribute our results to 
ethnical differences. No previous report regarding this population 
can confirm or oppose our results, which are similar to those ones 
reported by Xu et al. [19]. 1 of 3 ADPKD patients shows multiple IAs 
[8], while in our series we found only 1 patient with 2 IAs (a 6 mm 
MCA bifurcation IA and a 3 mm ICA IA). Furthermore, large IAs 
(>15 mm) seem to occur more often in in ADPKD patients (27%) 
than in general population (10%) [20]. We detected small IAs with a 
mean diameter of 5 mm. As reported by Hughes [21], the majority of 
unruptured IAs detected by MRA screening in patients with ADPKD 
is small, with over 90% smaller than 10 mm and over 70% smaller 
than 6 mm in diameter, as in our study population. According to the 
ISUIA study, they should belong to the lowest-risk natural history 
group [22]. Whether the very low risk of rupture of small IAs in the 
general population found in the ISUIA can be extrapolated to patients 
with ADPKD remains to be proved. Nevertheless, the incidence of 
ruptured IAs in patients with ADPKD is estimated to be fivefold that 
of the general population, as well as the prevalence of asymptomatic 
IAs in these patients. The mean age of rupture of IAs in ADPKD 
patients is approximately 40 years, which is similar to that observed 
in other familial forms of IAs, but occurs 10 years earlier than in the 
general population [23].
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The most frequent site of ruptured IAs in patients with ADPKD is 
the anterior communicating artery (AcA), which is similar to patients 
without ADPKD [23]. We had only 1 patient who developed SAH for 
a ruptured IA: she had a 5 mm AcA aneurysm with irregular walls. 
We can hypothesize that the rupture can be linked to the poor efficacy 
of the conservative treatment, especially to the inadequate control of 
hypertension. A positive family history, defined as first or second 
degree relative with SAH or IAs, was reported in 40% of patients with 
ADPKD. In patients without ADPKD the proportion of patients with 
an affected first or second degree relative approximates 14% [22]. In 
our study, we found prevalence of 41.1% for positive family history 
and of 50% in ADPKD patients with IAs. The importance of a MRA 
screening program for IAs in ADPKD population has been widely 
assessed [24-26]. The lower risk rates of morbidity and mortality 
achieved with aneurysm surgery prior to hemorrhage, combined 
with advances in imaging techniques and endovascular management, 
have made screening for asymptomatic aneurysms more attractive, 
particularly in high-risk groups such ADPKD patients [27]. The risk 
of screening asymptomatic IAs followed by treatment should be 
weighed against the risks of SAH, linked to a family history of IAs 
and the higher aneurysm rate in these patients: ADPKD patients 
with a family history of IAs have a higher prevalence of IAs and may 
be at increased risk for rupture. Furthermore, IAs in patients with 
familial SAH and ADPKD tend to rupture at a smaller size than those 
in people without these conditions [23,26]. The strategy of choice 
should aim at improved life expectancy or the best quality-adjusted 
survival. On account of this, we decided to study ADPKD patients 
although asymptomatic and recommended treatment despite the 
small sizes of the aneurysms. One decision analysis suggested that 
MRA screening for asymptomatic IAs in ADPKD young individuals, 
as our study group, would increase life expectancy and reduce 
socioeconomic burden of ADPKD [26]. The decision of screening 
Figure 1: 48-year-old woman with autosomal-dominant polycystic kidney disease and intracranial aneurysm. CT-angiography (MPR, a) and MR-angiography 
(3D TOF, MIP and VR, b-c) show the presence of a small saccular aneurysm of the left ICA ophthalmic segment (white arrow).
Figure 2: 48-year-old woman with autosomal-dominant polycystic kidney disease and intracranial aneurysm (same case). Digital subtraction angiography 
(a) confirms the presence of the aneurysm of the left ICA ophthalmic segment; follow-up DSA (b) 3 months after treatment by flow-diverter device (PIPELINE 
EV3 Chestnut Medical Inc.) demonstrates total occlusion of the sack (black arrow).
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should also take into consideration patients’ knowledge and feeling 
about the risks of IAs rupture and prophylactic treatment. Although 
IAs found in our screening program are small and in the anterior 
circulation, we assumed that any benefit from microsurgical or 
endovascular approaches would be balanced against their significant 
cost and the anxiety it would generate in those in whom IA was found 
but no treatment proposed. We opted for treatment by flow-diverter 
devices (FDD) in three patients, because on our experience we 
achieved good results using these devices for small IAs with relatively 
wide neck [27,28,29] although the majority of trials proved their 
efficacy particularly for wide-neck or large/giant aneurysms. Many 
authors sustain the high cost of FDD against the cheapest use of coils; 
however, we opted for FDD as we know from the literature review 
that a big part of recanalization of IAs treated by coiling involves 
mostly small and wide-neck IAs, as those found in our study series. 
Nevertheless, decisions regarding the management of unruptured IAs 
are complex and multiple factors need to be considered, including 
size, morphology, and site, prior and familial history of SAH, patient 
age and general health. However, because >50% of ruptured IAs in 
ADPKD patients are >10 mm in diameter, the treatment of IAs > 5 
mm is increasingly considered, especially in young individuals who 
have an IA treatable by coiling or stenting [26-28]. We believe that 
these patients should be assessed on an individual basis taking all the 
relevant risk factors into account before deciding treating or not for 
IAs. Moreover, we detected 2 patients with vascular dolichoectasia 
(1 of ICA and 1 of BA) in our study population: the patient with 
BA experienced also aortic dissection (type A) 9 months before 
performing MRI. Examiners should direct their attention to this vessel 
abnormality in ADPKD patients, because dolichoectatic vessels are 
of clinical importance as a source of potential complications [30,31]. 
Limitations of the present study include the relatively low number 
of subjects, which could explain the main differences between our 
results and the previous literature, as well as the limited clinical data.
In conclusion, the prevalence of asymptomatic IAs in our study 
(16.1%), higher compared to the general population (1%) and similar 
to literature reports in ADPKD (6-16%), confirms the importance 
of the MRA study of the intracranial circle in these patients, even 
if asymptomatic. Decisions about the management of eventually 
discovered IAs should be based on multiple factors, assessing any patient 
on an individual basis taking all the relevant risk factors into account.
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